GW Pharmaceuticals: Featured Cannabis Stock
[stock-quotes-list stockExchange=”NYSENasdaq” width=”100%” symbols=”GWPH” allowSort=”false” includeChart=”true” logoMaxHeight=”20px” logoMaxWidth=”90px” height=”100%” culture=”English-US”]
GWPH (Nasdaq), GWPH (London)
Should you invest in GW Pharmaceuticals? Recommendation: Keep Reading
GW Pharmaceuticals is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.
GW is the leading biopharma company focused on discovering, developing and commercializing new therapeutics from its proprietary CBD formulations for a broad range of diseases.
GW commercialized the world’s first plant-derived CBD prescription drug, Sativex (nabiximols), approved for the treatment of spasticity from multiple sclerosis in over 25 countries outside the United States.
On June 25, 2018, the US FDA approved Epidiolex oral solution for the treatment of seizures from Lennox-Gastaut syndrome (LGS) and Dravet syndrome (both epilepsies) in patients two years or older. Epidiolex is made from crystallized CBD, where they remove all other cannabinoids, terpenes, and tetrahydrocannabinol (THC).
The approval process included testimony from the public about how life-changing the oral CBD product had been during clinical trials. In the study, 44% of patients using Epidiolex to treat highly treatment-resistant LGS had a significant reduction in the frequency of drop seizures, a type of seizure where a person suddenly falls down.
Epidiolex is the first prescription pharmaceutical derived from cannabidiol (CBD), and the first anti-epileptic drug (AED). Drug awareness is deemed high among the target market and demand is growing.
Market Cap: US $2.68 bil
Enterprise Value: US $2.17 bil
Number of employees: 901
GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
Epidiolex sales have begun in the US, and they are booming. GW reported $296 million from Epidiolex in 2019. With European sales and Sativex coming along the company has no problems with cash flow and reports almost $540 million in cash on hand.
The Epidiolex market is two specific forms of childhood epilepsy, LGS and Dravat’s Syndrome. There are 4,000-19,000 kids in the USA with LGS, and roughly 5,000 children with Dravat’s Syndrome in the USA.
On February 11th, 2020, prior to any coronavirus outbreaks in the USA, GW was trading at $129.96. Just 1.5 months later, share prices have dropped over 40%. If there was any time to get a discounted stock, this may be it. The price to sales is 9.12, slightly higher than the pharma industry average of 7.5. Price to book is 3.91 and EV/Revenue is at 6.98. What does all this fundamental analysis mean? The stock is not currently overpriced (which it was just a few months ago). We think this is an excellent buy opportunity and are excited to watch their revenue increase in 2020 with Sativex and eventually their CBDV drug in the coming years.
GW Pharmaceuticals: Featured Cannabis Stock
About Cannin: Your Marijuana Investment Experts
Cannin is your trusted resource for information about marijuana and hemp stock investment opportunities. Our global team of experts evaluates all emerging marijuana and hemp stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana and hemp stock investments for 2020. We provide the latest marijuana investment and hemp investment news and analysis.
Use Cannin as your resource for breaking cannabis and hemp investing news, featured cannabis and hemp company analysis, comprehensive cannabis and hemp stock reports, or get your free trial now and use our Smart Stock Algorithm to take the guesswork out of profiting from the cannabis industry. Is it too late to invest in marijuana or hemp stocks? No! This is the perfect time to invest in companies like GW Pharmaceuticals: Featured Cannabis Stock.
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana and hemp stocks is now. Are you looking to buy stock in hemp companies or marijuana companies for 2020? Interested in emerging penny hemp stock companies? Looking for the best Canadian marijuana stocks to invest in? We can help.
Predict price movements of marijuana and hemp stocks several hours in advance with our proprietary algorithmic stock trading software.
Profit from the best marijuana stocks – we’ll show you how at cannin.com